Latest news for  (OTC:VNCUF) Stock

Piper Sandler analyst Crispin Love maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Neutral and raises the price target from $168 to $179.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on Blackstone, Raises Price Target to $179

WIIM

NUVB

Nuvation Bio shares are trading higher after the company announced the FDA accepted the New Drug Application for taletrectinib for the treatment of advanced ROS1+ NSCLC.

Anebulo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today announced a positive regulatory update and the close of a capital raise.
<ul>
<li>In a Phase 2 proof-of-concept study, Anebulo enrolled 134 adult subjects challenged with oral delta-9-tetrahydrocannabinoil ("THC"), oral selonabant blocked or reversed key CNS effects of THC, establishing the clinical path for intravenous selonabant for a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of acute cannabis-induced toxicity in children</li>
<li>Anebulo met with FDA to discuss the development of intravenous selonabant and the initial plan for clinical testing</li>
<li>FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity, and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediatric indication</li>
<li>Anebulo plans to begin its Phase I SAD study of IV selonabant in healthy adults in 1H25</li>
<li>Anebulo entered into a definitive stock purchase agreement with 22NW, a company controlled by one of its directors, Nantahala Capital and an additional existing investor for the issuance and sale of 15.2 million shares of common stock for gross proceeds of $15 million in a private placement offering priced at-the-market under Nasdaq rules</li>
<li>In exchange for purchasing $10 million of shares of common stock in the private placement, Anebulo intends to modify the Loan and Security Agreement (LSA) that was entered into with 22NW and JFL Capital Management by reducing the maximum loan size to approximately $3 million, which reduces the LSA to just under the securitization threshold, and the removal of any securitization</li>
</ul>

Biotech

General

ANEB

Anebulo Pharmaceuticals Announces FDA Feedback For IV Selonabant To Address Cannabis-Induced Toxicity In Children And Completes $15M Capital Raise; Phase I Study Planned For 1H25

Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) has outperformed the market over the past 20 years by 2.05% on an annualized basis producing an average annual return of 10.3%. Currently, Chubb has a market capitalization of $109.65 billion. 
Buying $1000 In CB: If an investor had bought $1000 of CB stock 20 years ago, it would be worth $7,098.87 today based on a price of $272.01 for CB at the time of writing.
<h3>Chubb's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734963313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

In the current session, Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) is trading at $111.71, after a 0.29% decrease. Over the past month, the stock fell by 4.62%, and in the past year, by 11.31%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1734963307_0.png" alt="Past Year Chart" />

<h3>Comparing Global Payments P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Global Payments has a lower P/E than the aggregate P/E of 46.95 of the Financial Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734963307_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

P/E Ratio Insights for Global Payments

First Busey Corporation ("First Busey") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUSE#NASDAQ">BUSE</a>), the holding company of Busey Bank, and CrossFirst Bankshares, Inc. ("CrossFirst") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFB#NASDAQ">CFB</a>), the holding company of CrossFirst Bank, today jointly announced that First Busey shareholders and CrossFirst shareholders have each voted to adopt and approve, as applicable, all proposals relating to the previously announced merger in which First Busey will acquire CrossFirst. The special shareholder meetings were held on Friday, December 20, 2024.

BUSE

First Busey And CrossFirst Bankshares Announce Each Co's Shareholder Approvals Of Merger

Benchmark analyst Robert Wasserman reiterates Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Buy and maintains $135 price target.

Reiteration

LGND

Benchmark Reiterates Buy on Ligand Pharmaceuticals, Maintains $135 Price Target

Loop Capital analyst Mark Schappel maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $185 to $205.

SNOW

Loop Capital Maintains Buy on Snowflake, Raises Price Target to $205

Intuitive Machines Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares are trading higher on Monday. The company announced that it secured additional contracts from NASA&#8217;s Near Space Network for <a href="https://www.benzinga.com/pressreleases/24/12/g42645401/intuitive-machines-expands-data-transmission-services-for-lunar-and-deep-space-missions">Direct-to-Earth services</a>.
What Happened: Intuitive Machines announced Monday morning that it received two new contract awards from NASA&#8217;s Near Space Network for subcategory 1.2 and subcategory 1.3. 
Subcategory 1.2 covers DTE Geostationary to Cislunar DTE Services, offering enhanced data transmission capabilities and autonomous operations. Subcategory 1.3 covers xCislunar DTE Services, addressing mission needs for highly elliptical orbits and deep space operations.
Both contracts are firm-fixed-price, indefinite-delivery/indefinite-quantity task orders designed to bolster NASA&#8217;s Lunar Exploration Ground Segment.&nbsp;
&#8220;We are privileged to help NASA deliver essential data and transmission services that support missions navigating the critical pathways between Earth, the Moon, and beyond. We believe these new awards complement our existing NSN contract and will expand our space communications and navigation service offerings,&#8221; said Steve Altemus, CEO of Intuitive Machines.
&#8220;They position us to capitalize on the&nbsp;$4.82 billion&nbsp;maximum potential value of the NSN contract, while supporting NASA&#8217;s Artemis campaign and commercial endeavors to expand the lunar economy.&#8221;
See Also: <a href="https://www.benzinga.com/general/space/24/12/42612382/spacex-to-launch-2-more-private-astronaut-missions-to-iss">SpaceX To Launch 2 More Private Astronaut Missions To ISS</a>
The contract awards come after NASA awarded Intuitive Machines a <a href="https://www.benzinga.com/news/24/09/40919566/intuitive-machines-stock-is-soaring-wednesday-whats-going-on">Near Space Network contract</a> for communication and navigation services related to subcategory 2.2 in September. 
Project timelines for these contracts span from February 2025 to September 2029, with an additional five-year option period that could extend contracts through September 2034.
LUNR Price Action: <a href="http://benzinga.com/quote/lunr">Intuitive Machines shares</a> were up 5.08% at $14.27 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Intuitive Machines.

Contracts

Sports

Movers

LUNR

Intuitive Machines Stock Is Moving Higher Monday: What's Going On?

Filing Form 10-K for the Year Ended June 30, 2024
Filing Form 10-Q for the Quarter Ending September 30, 2024
TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic reports that the Company now complies with the Rule and accordingly these matters are now closed.

UPXI

Upexi Regains Compliance With NASDAQ Listing Standards

Benchmark analyst Mark Palmer reiterates Galaxy Digital Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#TSX">GLXY</a>) with a Buy and maintains C$41 price target.

TSX:GLXY

Benchmark Reiterates Buy on Galaxy Digital Hldgs, Maintains C$41 Price Target

An AI-Driven Minimal Residual Disease Detection Platform For Lung Cancer, In Partnership With Flomics Biotech, Uppsala Universitet, And Oncodia

RENB

RenovaroCube Secures Eurostars Approval For Lumina Project

GIFT

Giftify's CardCash Reports 57% YoY Growth In Gift Card Sales During Black Friday To Cyber Monday, Reaching $3.1M Face Value Across 8,825 Orders With $347 Average Order Size

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.carlisle.com%2FHome%2Fdefault.aspx&amp;esheet=54170360&amp;newsitemid=20241223924612&amp;lan=en-US&amp;anchor=Carlisle+Companies+Incorporated&amp;index=1&amp;md5=b577e8900fa6a956ebf13de79f31d88d">Carlisle Companies Incorporated</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) today announced that it has entered into a definitive agreement to acquire Texas-based expanded polystyrene insulation manufacturer ThermaFoam. Founded in 1978 and located in the Dallas/Fort Worth area, ThermaFoam serves the commercial, residential, and infrastructure construction markets through both the ThermaFoam and PowerFoam brands.
The purchase of ThermaFoam is consistent with Carlisle's Vision 2030 strategy and strategic pivot to a pure play building products company with increased investment in innovation and synergistic M&amp;A.

Carlisle Companies To Acquire ThermaFoam, A Manufacturer Of Expanded Polystyrene Insulation Products; No Financial Terms Disclosed

Has Until February 17, 2025, To Submit Compliance Plan And Expects To Regain Compliance Within 60 Days

CMTL

Comtech Receives Nasdaq Notification For Late Filing Of Q1 Form 10-Q

In a world where convenience drives decision-making, embedded finance is reshaping how people interact with money. At a recent panel discussion at the <a href="https://benzinga.swoogo.com/fintech-awards/6073689">Benzinga Fintech Deal Day &amp; Awards</a> event, industry leaders explored how these financial solutions integrate seamlessly into daily life, addressing accessibility, efficiency, and consumer demand.
<h4 class="wp-block-heading">Real-Time Solutions For Everyday Needs</h4>
Rob Nardelli, director of commercial banking at DailyPay, highlighted the practical benefits of embedded finance through earned wage access. This solution allows employees to access wages as they earn, bypassing traditional pay cycles. Nardelli shared a striking example of a customer using DailyPay's app to avoid an awkward moment on a first date. 
"Within seconds, the money hit his account, swiped his card, filled his tank, and got on his merry way," he said, adding that the couple is now happily married.
Diksha Gera, a senior analyst at Bloomberg Intelligence, emphasized the convenience embedded finance offers, particularly when traditional banking systems fall short. Reflecting on her experience of moving to the U.S., Gera explained how financial solutions must be embedded into decision-making moments. "Nobody wants to make banking another task to do in the day," she said, noting that accessibility is crucial to meeting consumer expectations.
<h4 class="wp-block-heading">The Push For Real-Time Payments</h4>
Real-time payments (RTP) are a critical component of embedded finance, enabling instantaneous transactions that address urgent financial needs. Nardelli explained how RTP powers DailyPay's earned wage solution, providing funds when needed. "The faster the payment, the faster the fraud," he acknowledged, but stressed that thorough due diligence on the front end mitigates risks and ensures reliability.
Gera noted that while countries like India and Brazil lead in RTP adoption, the U.S. faces challenges due to entrenched consumer habits and reliance on credit cards. However, she pointed out that support from major players could accelerate adoption, stating, "It's a difficult proposition, but we're watching for momentum."
<h4 class="wp-block-heading">Regulatory Hurdles And Collaboration</h4>
The conversation also turned to the role of regulation in shaping the future of embedded finance. Sarah Biller, co-founder of FinTech Sandbox, discussed the importance of compliance, particularly for partnerships between banks and FinTech firms. "If you seek to embed FinTech solutions… recognize that your banker who's going to contribute their rails [faces] very harsh regulatory penalties."
While regulatory clarity is improving, banks and FinTechs must work together to overcome challenges such as anti-money laundering (AML) and know-your-customer (KYC) requirements. Biller encouraged FinTechs to view banks as partners, adding, "Main Street is no longer just that sidewalk. It's a digital environment."
<h4 class="wp-block-heading">The Road Ahead</h4>
Panelists agreed that embedded finance transforms the financial landscape, offering practical and accessible solutions. From earned wage access to real-time payments and beyond, these innovations meet consumers where they are, creating opportunities to rethink traditional systems. As Nardelli succinctly said, "The future is about giving people the tools they need when they need them."
This discussion highlighted the potential of embedded finance to address real-world challenges and improve financial accessibility, marking a step forward in how money moves through everyday life.
Image: Shutterstock

Events

'Nobody Wants To Make Banking Another Task' — The Push For Financial Integration

USNA

USANA Acquires 78.8% Stake In Hiya Health For $205M, Expanding Into Direct-To-Consumer Children's Wellness Market; Deal Expected To Add $103M In Sales And Boost 2025 Adjusted EBITDA Immediately

KVYO

Klaviyo shares are trading higher after Loop Capital maintained a Buy rating on the stock and raised its price target from $45 to $60.

Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and maintains $114 price target.

MMSI

Barrington Research Maintains Outperform on Merit Medical Systems, Maintains $114 Price Target

Honda Motor shares are trading higher after the company announced it agreed to begin discussions and consideration toward a business integration with Nissan Motor.

Comments

News

Latest news for (OTC:VNCUF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga